Literature DB >> 15882315

Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease.

Justin Silver1, Ronen Levi.   

Abstract

Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Small decreases in serum Ca(++) and more prolonged increases in serum phosphate (P) stimulate the parathyroid (PT) to secrete parathyroid hormone (PTH), while 1,25(OH)(2)-vitamin D(3) decreases PTH synthesis and secretion. A prolonged decrease in serum Ca(++) and 1,25(OH)(2)D(3), or increase in serum P, such as in patients with chronic renal failure, leads to the appropriate secondary increase in serum PTH. This secondary hyperparathyroidism involves increases in PTH gene expression, synthesis, and secretion, and, if chronic, to proliferation of the parathyroid cells. A low serum Ca(++) leads to an increase in PTH secretion, PTH mRNA stability, and parathyroid cell proliferation. Pi also regulates the parathyroid in a similar manner. The effect of Ca(++) on the parathyroid is mediated by a membrane Ca(2+) receptor (CaR). 1,25(OH)(2)D(3) decreases PTH gene transcription. Ca(2+) and P regulate the PTH gene post-transcriptionally by regulating the binding of parathyroid cytosolic proteins, trans factors, to a defined cis sequence in the PTH mRNA 3'-untranslated region (UTR), thereby determining the stability of the transcript. The parathyroid trans factors and cis elements have been defined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882315     DOI: 10.1111/j.1523-1755.2005.09501.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  17 in total

Review 1.  Phosphate sensing.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

2.  Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D.

Authors:  M Fleseriu; A A Licata
Journal:  Osteoporos Int       Date:  2006-10-24       Impact factor: 4.507

3.  Fulminant Skeletal Failure in a Centenarian: The Impact of Nutrition and Immobility.

Authors:  M Brennan; N O'Flaherty; P M O'Shea; S O'Keeffe; E Mulkerrin
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

4.  Application of total parathyroidectomy with auto-transplantation for uremia secondary hyperparathyroidism treatment.

Authors:  Ying Jing; Hanhui Zhao; Yanming Ge; Fengyu Jia; Qingqing He; Suxia Wang; Jianzhong Meng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 5.  Can parathyroid hormone be used as a biomarker for heart failure?

Authors:  Sumeet Gandhi; Robert B H Myers
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

Review 6.  Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?

Authors:  James B Wetmore; L Darryl Quarles
Journal:  Nat Clin Pract Nephrol       Date:  2008-10-28

7.  Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism.

Authors:  Kelly Lauter; Andrew Arnold
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

8.  Prevalence of Hyperparathyroidism, Mineral and Bone Disorders in Children with Advanced Chronic Kidney Disease.

Authors:  Sherif El Desoky; Youssef M K Farag; Eatidal Safdar; Mohamed Ahmed Shalaby; Ajay K Singh; Jameela A Kari
Journal:  Indian J Pediatr       Date:  2016-01-30       Impact factor: 1.967

9.  Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.

Authors:  James B Wetmore; L Darryl Quarles
Journal:  Int J Nephrol Renovasc Dis       Date:  2008-11-13

10.  Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial.

Authors:  Katja Schlosser; Johannes A Veit; Stefan Witte; Emilio Domínguez Fernández; Norbert Victor; Hans-Peter Knaebel; Christoph M Seiler; Matthias Rothmund
Journal:  Trials       Date:  2007-09-18       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.